<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332240</url>
  </required_header>
  <id_info>
    <org_study_id>EVITA001</org_study_id>
    <nct_id>NCT01332240</nct_id>
  </id_info>
  <brief_title>External ValidatIon Trial of ASTER Trial</brief_title>
  <acronym>EVITA</acronym>
  <official_title>External ValidatIon Trial of Aster: the Need for Surgical Staging After Echo-endoscopic Mediastinal Staging in Clinical N2/3 Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely
      spread in Belgium, the investigators aimed to determine the number of mediastinoscopies
      needed to detect one additional mediastinal lymph node invasion during routine clinical
      practice in the staging of potentially resectable clinical stage III non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background : The observation made by the ASTER investigators might be criticized as all
      procedures were performed in highly experienced centers. To date, the number of
      mediastinoscopies needed to detect one additional N2/3 disease in the routine clinical
      practice of chest physician performing endosonography for mediastinal staging is unknown. The
      investigators therefore seek to answer whether a negative endosonography should routinely be
      followed by mediastinoscopy in day to day clinical practice.

      Aim : As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is
      widely spread in Belgium, the investigators aimed to determine the number of
      mediastinoscopies needed to detect one additional mediastinal lymph node invasion during
      routine clinical practice.

      Setting : centers in Belgium with EBUS-TBNA and/or EUS-FNA experience in at least 20 patients
      agreed to participate and will include their patients.

      Design : Prospective national observational multicenter study. All patients with clinical
      N2/3 disease based on CT and/or PET requiring invasive mediastinal staging will primarily
      undergo invasive mediastinal staging with endosonography (EBUS +/- EUS). A subsequent
      cervical mediastinoscopy will be performed in case no mediastinal lymph node involvement was
      found with endosonography. Local surgeons perform these procedures according to their
      institutional practice. Thoracotomy with mediastinal lymph node dissection will be the gold
      standard for invasive mediastinal staging, in case no mediastinal lymph node metastases were
      found during clinical staging including endosonography and mediastinoscopy.

      Patients : The study will include 255 patients, based on the calculation of 15 consecutive
      patients in each participating center, in order to validate the ASTER data.

      Primary endpoint : The number of mediastinoscopies needed to detect one additional N2/3.

      Secondary endpoints : The number of mediastinal lymph nodes stations sampled with
      endosonography ; the median size of largest mediastinal lymph node sampled; characteristics
      of mediastinal nodal disease missed by endosonography.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of mediastinoscopies needed to detect one additional N2/3</measure>
    <time_frame>1 month</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of mediastinal lymph nodes stations sampled with endosonography</measure>
    <time_frame>1 month</time_frame>
    <description>Characteristics of nodal staging; the median size of largest mediastinal lymph node sampled; characteristics of mediastinal nodal disease missed by endosonography.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Stage III Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endosonography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic ultrasonography</intervention_name>
    <description>in order to stage the mediastinum</description>
    <arm_group_label>Endosonography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients with (suspected) NSCLC in whom invasive mediastinal staging is
             required based on presence of ACCP group B mediastinal lymph nodes and/or FDG-PET
             positive (visual interpretation of FDG uptake in mediastinal nodes as present)
             mediastinal lymph nodes (either ACCP group B or ACCP group D) in lymph node stations
             2, 4, 7, 8 or 9 (see Appendix).

          -  Potentially operable and resectable disease.

          -  Radically treated previous extrathoracic malignancies are allowed whenever the
             extrathoracic malignancy is considered in remission, and a primary parenchymal lung
             tumour is present.

          -  Provision of a written informed consent.

        Exclusion Criteria:

          -  Previous cervical mediastinoscopy.

          -  Uncorrected coagulopathy.

          -  Former treatment for a lung cancer.

          -  Patient unable to give a written informed consent.

          -  Absence of a primary parenchymal lung tumour.

          -  Distant metastases (cM1 disease) after routine clinical work-up.

          -  Clinical N2/3 disease only based on suspected mediastinal lymph nodes in stations 5 or
             6.

          -  Patients belonging to ACCP groups A and C based on CT scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Dooms</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Tournoy</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ghent Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Dooms, MD, PhD</last_name>
    <phone>0032 16 34.09.49</phone>
    <email>christophe.dooms@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kurt Tournoy, MD, PhD</last_name>
    <email>kurt.tournoy@ugent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Middelheim Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Galdermans</last_name>
    </contact>
    <investigator>
      <last_name>Danny Galdermans</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Heremans</last_name>
    </contact>
    <investigator>
      <last_name>Andre Heremans</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Jan Ziekenhuis Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca De pauw</last_name>
    </contact>
    <investigator>
      <last_name>Rebecca De Pauw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Leduc</last_name>
    </contact>
    <investigator>
      <last_name>Dimitri Leduc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Pierard</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Pierard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Monica</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Vandenbroucke</last_name>
    </contact>
    <investigator>
      <last_name>Elke Vandenbroucke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Germonprez</last_name>
    </contact>
    <investigator>
      <last_name>Paul Germonprez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Pat</last_name>
    </contact>
    <investigator>
      <last_name>Karin Pat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom De Keukeleire</last_name>
    </contact>
    <investigator>
      <last_name>Tom De Keukeleire</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier Jolimont</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Clinckart</last_name>
    </contact>
    <investigator>
      <last_name>Fréderic Clinckart</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Bolly</last_name>
    </contact>
    <investigator>
      <last_name>Antoine Bolly</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mariaziekenhuis</name>
      <address>
        <city>Overpelt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Pollefliet</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Pollefliet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Ziekenhuis</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingel Demedts</last_name>
    </contact>
    <investigator>
      <last_name>Ingel Demedts</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Elisabeth en Sint-Jozef ziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Driesen</last_name>
    </contact>
    <investigator>
      <last_name>Peter Driesen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Augustinus ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Van Grieken</last_name>
    </contact>
    <investigator>
      <last_name>Sofie Van grieken</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc</name>
      <address>
        <city>Woluwe</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiery Pieters</last_name>
    </contact>
    <investigator>
      <last_name>Thiery Pieters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>staging</keyword>
  <keyword>endosonography</keyword>
  <keyword>lung cancer</keyword>
  <keyword>stage III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

